NEW YORK & SAN DIEGO--(BUSINESS WIRE)--A Phase 1 study of a preventive HIV vaccine testing a novel delivery mechanism known as electroporation – the use of electrical pulses to increase the immune responses elicited by DNA vaccines – was recently completed in New York City. The results show that TriGrid™, a technology developed by Ichor Medical Systems, Inc., helped to enhance the immunogenicity of the vaccine tested. Compared to intramuscular injection, the conventional mode of delivery, electroporation significantly enhanced detectable immune responses to the DNA vaccine, known as ADVAX, which was tested in 40 healthy human volunteers. Initial results were presented at the end of October at the AIDS Vaccine Conference in Paris, France.
